Evidence map›Paper›PMID 34536950›Full record

ArticleAging2021

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen.

Liang Wang, Yinfeng Lyu, Yuqing Li, Kunping Li, Hui Wen, Chenchen Feng, Ning Li

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Liang WangDepartment of Urology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China.
Yinfeng LyuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Yuqing LiDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Kunping LiDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Hui WenDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Chenchen FengDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Ning LiDepartment of Urology, Fourth Affiliated Hospital of China Medical University, Shenyang 100032, Liaoning Province, P.R. China.
Huashan Hospital · CNFourth Affiliated Hospital of China Medical University · CNTianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is a rare but aggressive disease that lacks definitive treatment. We aim to evaluate role of ASXL1 in ACC and exploit its therapeutic merits therein. We performed

Indexed as

Drug Resistance, NeoplasmAdrenal Cortex NeoplasmsAdrenocortical CarcinomaAntibiotics, AntineoplasticAntineoplastic AgentsAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsCisplatinDatasets as TopicDoxorubicinEtoposideHumansRepressor ProteinsAntibiotics, AntineoplasticAntineoplastic AgentsAntineoplastic Agents, PhytogenicASXL1 protein, humanCisplatinDoxorubicinEtoposideRepressor Proteinsadrenocortical carcinomaASXL1chemoresistance

Identifiers

PMID34536950
PMCPMC8507286
OpenAlexW3200616826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.